Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of recombinant human coagulation factor VIII prophylaxis in previously treated children with severe hemophilia A
CTR20211446Phase 3Completed
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Chengdu Rongsheng Pharmaceutical. Started Oct 2021; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20211446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211446.